Your session is about to expire
← Back to Search
ARV-110 + Abiraterone for Prostate Cancer
Study Summary
This trial is testing a new combination therapy for metastatic prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any active, uncontrolled infections including HIV/AIDS or hepatitis.My PSA levels have increased 16 weeks after starting abiraterone.My PSA levels have increased 16 weeks after starting abiraterone.I am currently on stable doses of abiraterone and a steroid for my metastatic prostate cancer.I have stomach or bowel issues but not severe acid reflux needing strong medication.I haven't had any cancer except for certain skin cancers or localized cancer that hasn't spread in the last 3 years.I have not had major surgery within the last 4 weeks.My prostate cancer diagnosis was confirmed through a lab test.I am fully active or restricted in physically strenuous activity but can do light work.I have brain metastases that are either untreated or need steroids.My PSA levels have increased twice after starting abiraterone treatment.I am currently on abiraterone and not showing signs of cancer progression.I have been treated with specific prostate cancer medications or experimental therapies.I am not on medications that interact badly with the trial drugs.I have had serious heart rhythm problems in the last 6 months.My liver disease is severe (Child-Pugh C).My high blood pressure is not controlled by medication.I am currently on stable doses of abiraterone and a steroid for my advanced prostate cancer.I haven't had radiation therapy in the last 4 weeks or to more than 25% of my bone marrow.I am currently benefiting from abiraterone without signs of my cancer worsening on scans.My PSA levels have increased twice after starting abiraterone treatment.I am currently on hormone therapy for cancer or have had an orchiectomy.I am currently on hormone therapy for cancer or have had an orchiectomy.I haven't had chemotherapy, immunotherapy, or other cancer treatments except for GnRH agonists in the last 28 days.My prostate cancer diagnosis was confirmed through a lab test.I have not had a heart attack, severe chest pain, heart surgery, stroke, or significant blood clot in the last year.
- Group 1: Oral tablet(s) in combination with abiraterone and a corticosteroid.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has there been previous research exploring the synergy between ARV-110 and Abiraterone?
"ARV-110 in Combination with Abiraterone was initially studied at Rosemere Cancer Centre at Royal Preston Hospital more than 15 years ago. At present, 100 trials have been completed while 98 are actively being conducted across multiple sites, a significant portion of which is located in Columbus, Ohio."
What has been revealed regarding the safety of ARV-110 in conjunction with Abiraterone?
"Our assessment rated the safety of ARV-110 in Combination with Abiraterone a 1 due to it being in Phase 1, where there is only limited evidence for its efficacy and safety."
Are there still vacancies for participants in the clinical trial?
"Clinicaltrials.gov confirms that this research project is actively inviting volunteers to participate, having been first published on February 1st 2022 and recently edited October 26th of the same year."
What is the aggregate size of this investigation's cohort?
"Affirmative. Clinicaltrials.gov data points to this investigation being open for applicants, the first advertisement having been released on February 1st 2022 and latest update being issued on October 26th 2022. 40 study participants must be recruited from 12 different sites."
How many locations are carrying out this clinical trial?
"The 12 sites presently running this trial are sprawled across the United States, including Columbus, Fort Myers, and Tampa. To reduce travel requirements if participating in the study, you may want to select a location closest to your residence."
Who else is applying?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger